Regorafenib
Regorafenib is an orally bioavailable, multi-targeted tyrosine kinase inhibitor active against key oncogenic and angiogenic receptors including RET, VEGFRs, and PDGFRβ. It exhibits potent antitumor and anti-angiogenic effects, validated in both in vitro assays and in vivo models of colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.
Product Specifications
CAS Number
755037-03-7
Product Name Alternative
BAY 73-4506
Field of Research
Cardiovascular Research
Purity
>98%
Bioactivity
Multi-kinase inhibitor; PDGF, VEGF etc
Form
Powder
Solubility
Soluble in DMSO up to 50 mg/ml
Smiles
CNC (=O) c1cc (Oc2ccc (NC (=O) Nc3ccc (Cl) c (c3) C (F) (F) F) c (F) c2) ccn1
Molecular Formula
C21H15ClF4N4O3
Molecular Weight
482.8
Storage Conditions
-20°C
Notes
For research use only.
Other Product Names
4-[4-[[[[4-Chloro-3- (trifluoromethyl) phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Canine Niemann-Pick C1-like protein 1 (NPC1L1) ELISA Kit
Recombinant Mouse SH3KBP1-binding protein 1 (Shkbp1)